Showing results (131-140 of 317) with videos related to

Sort By:
Pageof 32
Breast (Edinburgh, Scotland)|August 13, 2023
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in ItalyAlberto Zambelli, Marina Cazzaniga, Nicla La Verde, et al.
Cancers|December 8, 2020
Update on the Management of Breast Cancer during PregnancyFrancesca Poggio, Marco Tagliamento, Chiara Pirrone, et al.
Clinical Medicine Insights. Oncology|July 11, 2020
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast CancerFrancesca Parisi, Maria Grazia Razeti, Eva Blondeaux, et al.
NPJ Breast Cancer|January 28, 2026
Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncologyGiuseppe Di Grazia, Rodrigo Sánchez-Bayona, Climent Casals-Pascual, et al.
Expert Opinion on Investigational Drugs|May 3, 2018
Lenvatinib for the treatment of renal cell carcinomaGiandomenico Roviello, Silvia Paola Corona, Giovanni Bozza, et al.
Cancer Treatment Reviews|August 25, 2024
Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implicationsFrancesco Schettini, Federica Gattazzo, Sabrina Nucera, et al.
Plos One|July 24, 2026
Decision tree model to assess consequences and costs associated with therapy administration pathways for patients with HER2+ breast cancer in Italian oncological centersGiorgia Gribaudo, Carla Fornari, Ippazio Cosimo Antonazzo, et al.
Critical Reviews in Oncology/Hematology|November 12, 2019
Granular cell tumor of the breast: a multidisciplinary challengeFrancesco Meani, Simona Di Lascio, Wiebke Wandschneider, et al.
Therapeutic Advances in Medical Oncology|February 20, 2025
Different activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case reportMarta Perachino, Lucia Del Mastro, Giulia Buzzatti, et al.
Bone|August 29, 2006
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor loadDaniele Generali, Alfredo Berruti, Marco Tampellini, et al.
Pageof 32